SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-004325
Filing Date
2024-03-29
Accepted
2024-03-29 08:01:17
Documents
14
Period of Report
2024-03-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20240329x8k.htm   iXBRL 8-K 32761
2 EX-99.1 kala-20240329xex99d1.htm EX-99.1 154800
  Complete submission text file 0001558370-24-004325.txt   316964

Data Files

Seq Description Document Type Size
3 EX-101.SCH kala-20240329.xsd EX-101.SCH 3128
4 EX-101.LAB kala-20240329_lab.xml EX-101.LAB 15268
5 EX-101.PRE kala-20240329_pre.xml EX-101.PRE 9660
18 EXTRACTED XBRL INSTANCE DOCUMENT kala-20240329x8k_htm.xml XML 4676
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

IRS No.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 24802063
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)